SBFM Q2 2024 Earnings — Sunshine Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

SBFMSunshine Biopharma, Inc.

$6M

Q2 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$9M+67.3% YoY

Gross Profit

$2M24.8% margin

Operating Income

-$1M-13.6% margin

Net Income

-$494,000-5.3% margin

EPS (Diluted)

$-9.94

QoQ Revenue Growth

+23.4%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$29M

Total Liabilities

$6M

Stockholders' Equity

$23M

Cash & Equivalents

$12M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$6M	+67.3%
Gross Profit	$2M	$2M	+18.0%
Operating Income	-$1M	-$1M	-25.0%
Net Income	-$494,000	-$902,000	+45.2%